trendsraka.blogg.se -

#Nasdaq vmd software#
#Nasdaq vmd free#

Analyzing City (NASDAQ:CHCO) & CF Bankshares (NASDAQ:CFBK).

Netflix (NASDAQ:NFLX) and Redbox Entertainment (NASDAQ:RDBX) Head to Head Review.

Adit EdTech Acquisition (NYSE:ADEX) versus Innodata (NASDAQ:INOD) Financial Survey.

Critical Contrast: Astellas Pharma (OTCMKTS:ALPMY) vs.

Critical Analysis: Lithium (OTCMKTS:LTUM) & Augusta Gold (OTCMKTS:AUGG).

Comparing Dingdong (Cayman) (DDL) & Its Competitors.

Ubiquiti (NASDAQ:UI) versus Airspan Networks (NYSE:MIMO) Financial Review.

Financial Comparison: LogicMark (NASDAQ:LGMK) & Guardforce AI (NASDAQ:GFAI).

Financial Contrast: Charge Enterprises (NASDAQ:CRGE) & Ziff Davis (NASDAQ:ZD).

Comparing Zhong Yang Financial Group (NASDAQ:TOP) and LPL Financial (NASDAQ:LPLA).

DBV Technologies (NASDAQ:DBVT) & 4D Molecular Therapeutics (NASDAQ:FDMT) Head-To-Head Analysis.

Head-To-Head Contrast: Perpetua Resources (NASDAQ:PPTA) versus B2Gold (NYSE:BTG).

Financial Comparison: iHeartMedia (IHRT) and Its Rivals.

Analyzing Anywhere Real Estate (HOUS) & Its Competitors.

Rotork (OTCMKTS:RTOXY) versus Archaea Energy (NYSE:LFG) Financial Comparison.

Bit Origin (NASDAQ:BTOG) and Hormel Foods (NYSE:HRL) Financial Review.

Critical Comparison: On Track Innovations (OTCMKTS:OTIVF) vs.

Comparing New Gold (NYSE:NGD) & Nexa Resources (NYSE:NEXA).

Analyzing Berkshire Bancorp (OTCMKTS:BERK) & Republic First Bancorp (NASDAQ:FRBK).

#Nasdaq vmd free#

Receive News & Ratings for Viemed Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viemed Healthcare and related companies with 's FREE daily email newsletter. Get a free copy of the Zacks research report on Viemed Healthcare (VMD)įor more information about research offerings from Zacks Investment Research, visit

The Three Most Upgraded Stocks You Can Buy Now.

Volatile Times Are When AbbVie Shines the Brightest.

Cloudflare Inc: Struggling but With Great Opportunities.

#Nasdaq vmd software#

Why Investors Suddenly Love These 2 Software Stocks.

Get a free copy of the research report on Viemed Healthcare (VMD).

It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. Viemed Healthcare, Inc, through its subsidiaries, provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services to patients in the United States.

Hedge funds and other institutional investors own 63.94% of the company’s stock. The Manufacturers Life Insurance Company now owns 14,593 shares of the company’s stock valued at $76,000 after purchasing an additional 3,542 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Viemed Healthcare by 32.1% in the 4th quarter. purchased a new position in Viemed Healthcare in the 3rd quarter valued at $63,000. now owns 9,169 shares of the company’s stock valued at $48,000 after purchasing an additional 4,913 shares in the last quarter. lifted its holdings in Viemed Healthcare by 115.4% in the 4th quarter. Ahrens Investment Partners LLC purchased a new position in Viemed Healthcare in the 4th quarter valued at $41,000. National Bank of Canada FI purchased a new position in shares of Viemed Healthcare during the 4th quarter valued at approximately $31,000. Large investors have recently made changes to their positions in the company. The company has a market capitalization of $204.15 million, a PE ratio of 23.41 and a beta of 1.45. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.55 and a current ratio of 2.70. The company’s fifty day moving average price is $5.08 and its 200-day moving average price is $4.97. Viemed Healthcare has a one year low of $3.56 and a one year high of $9.12. According to data from, the company presently has a consensus rating of “Buy” and an average target price of $9.83. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. Separately, Zacks Investment Research raised shares of Viemed Healthcare from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th.